ProShare Advisors
CCCC icon

ProShare Advisors’s C4 Therapeutics CCCC Stock Holding History

ProShare Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,223
Closed -$26K – 2090
2025
Q1 		$26K Sell
16,223
-4,060
-20% -$12.1K ﹤0.01% 2016
2024
Q4 		$73K Buy
20,283
+9,204
+83% +$45.8K ﹤0.01% 2125
2024
Q3 		$63.1K Buy
+11,079
New +$66.7K ﹤0.01% 1950
2022
Q2 		– Sell
-12,296
Closed -$299K – 1835
2022
Q1 		$299K Sell
12,296
-2,989
-20% -$72.6K ﹤0.01% 1631
2021
Q4 		$492K Buy
15,285
+10,334
+209% +$409K ﹤0.01% 1456
2021
Q3 		$221K Sell
4,951
-3,983
-45% -$171K ﹤0.01% 1741
2021
Q2 		$338K Buy
+8,934
New +$320K ﹤0.01% 1812

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ProShare Advisors's CCCC Position: Q2 2025 in Review

ProShare Advisors sold out of C4 Therapeutics (CCCC) in Q2 2025, closing a stake of 16,223 shares — an estimated $26K sold.

ProShare Advisors first reported a position in CCCC in Q2 2021 and held it in 7 quarters. The position peaked at $492K in Q4 2021. 102 funds tracked by Wall St. Rank hold CCCC as of Q2 2025.

  • ProShare Advisors reported no remaining C4 Therapeutics position as of Q2 2025 after selling out during the quarter.
  • ProShare Advisors sold 16,223 C4 Therapeutics shares in Q2 2025, an estimated $26K.
  • ProShare Advisors first reported a position in C4 Therapeutics in Q2 2021 and held it in 7 quarters.
  • ProShare Advisors's C4 Therapeutics position peaked at $492K in Q4 2021.
  • 102 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.